The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial

Trials

Flávio Danni Fuchs¹  Leila Beltrami Moreira²  Miguel Gus¹  Sandra Costa Fuchs²  Denis Martinez²  Fábio Tremea Cichelero² 

[1] Division of Cardiology, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil;Postgraduate Studies Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

关键词: Amlodipine;    Chlorthalidone;    Diuretics;    Treatment;    Hypertension;    Sleep apnea;   

Others  :  807740
DOI  :  10.1186/1745-6215-15-1

 received in 2013-08-06, accepted in 2013-12-16,  发布年份 2014

【 摘 要 】

Background

Obstructive sleep apnea (OSA) and hypertension are well-known cardiovascular risk factors. Their control could reduce the burden of heart disease across populations. Several drugs are used to control hypertension, but the only consistently effective treatment of OSA is continuous positive airway pressure. The identification of a drug capable of improving OSA and hypertension simultaneously would provide a novel approach in the treatment of both diseases.

Methods/Design

This is a randomized double-blind clinical trial, comparing the use of chlorthalidone with amiloride versus amlodipine as a first drug option in patients older than 40 years of age with stage I hypertension (140 to 159/90 to 99 mmHg) and moderate OSA (15 to 30 apneas/hour of sleep). The primary outcomes are the variation of the number of apneas per hour and blood pressure measured by ambulatory blood pressure monitoring. The secondary outcomes are adverse events, somnolence scale (Epworth), ventilatory parameters and C reactive protein levels. The follow-up will last 8 weeks. There will be 29 participants per group. The project has been approved by the ethics committee of our institution.

Discussion

The role of fluid retention in OSA has been known for several decades. The use of diuretics are well established in treating hypertension but have never been appropriately tested for sleep apnea. As well as testing the efficacy of these drugs, this study will help to understand the mechanisms that link hypertension and sleep apnea and their treatment.

Trial registration

ClinicalTrials.gov: NCT01896661

【 授权许可】

   
2014 Cichelero et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National High Blood Pressure Education Program Coordinating Committee: The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
• [2]Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, et al.: 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462-1536.
• [3]Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR: Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med 2010, 11:441-446.
• [4]Silverberg D, Oksenberg A, Iaina A: The Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure and obstructive sleep apnea: let their silence not be matched by the silence of the ordinary physician. Arch Intern Med 1998, 158:1272-1273.
• [5]Goncalves SC, Martinez D, Gus M, De Abreu-Silva EO, Bertoluci C, Dutra I, Branchi T, Moreira LB, Fuchs SC, De Oliveira AC, Fuchs FD: Obstructive sleep apnea and resistant hypertension: a case–control study. Chest 2007, 132:1858-1862.
• [6]Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, Skatrud J: Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997, 157:1746-1752.
• [7]Silverberg DS, Oksenberg A, Iaina A: Sleep related breathing disorders are common contributing factors to the production of essential hypertension but are neglected, underdiagnosed, and undertreated. Am J Hypertens 1997, 10:1319-1325.
• [8]Fletcher EC, DeBehnke RD, Lovoi MS, Gorin AB: Undiagnosed sleep apnea in patients with essential hypertension. Ann Intern Med 1985, 103:190-195.
• [9]Stoohs R, Guilleminault C: MESAM 4: an ambulatory device for the detection of patients at risk for obstructive sleep apnea syndrome (OSAS). Chest 1992, 101:1221-1227.
• [10]De Oliveira AC T, Martinez D, Vasconcelos LF, Goncalves SC, Lenz MC, Fuchs SC, Gus M, Abreu-Silva EO, Moreira LB, Fuchs FD: Diagnosis of obstructive sleep apnea syndrome and its outcomes with home portable monitoring. Chest 2009, 135:330-336.
• [11]Balk EM, Moorthy D, Obadan NO, Patel K, Ip S, Chung M, Bannuru RR, Kitsios GD, Sen S, Iovin RC: Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. Rockville, MD: AHRQ Comparative Effectiveness Reviews; 2011.
• [12]Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ: Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002, 359:204-210.
• [13]Hla KM, Skatrud JB, Finn L, Palta M, Young T: The effect of correction of sleep-disordered breathing on BP in untreated hypertension. Chest 2002, 122:1125-1132.
• [14]Wright J, Johns R, Watt I, Melville A, Sheldon T: Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence. BMJ 1997, 314:851-860.
• [15]Smith I, Lasserson TJ, Wright J: Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006, CD003002.
• [16]Chiu KL, Ryan CM, Shiota S, Ruttanaumpawan P, Arzt M, Haight JS, Chan CT, Floras JS, Bradley TD: Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. Am J Respir Crit Care Med 2006, 174:1378-1383.
• [17]Redolfi S, Yumino D, Ruttanaumpawan P, Yau B, Su MC, Lam J, Bradley TD: Relationship between overnight rostral fluid shift and obstructive sleep apnea in nonobese men. Am J Respir Crit Care Med 2009, 179:241-246.
• [18]Su MC, Chiu KL, Ruttanaumpawan P, Shiota S, Yumino D, Redolfi S, Haight JS, Bradley TD: Lower body positive pressure increases upper airway collapsibility in healthy subjects. Respir Physiol Neurobiol 2008, 161:306-312.
• [19]Yumino D, Redolfi S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD: Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 2010, 121:1598-1605.
• [20]Verel D: Observations on the effect of posture on the distribution of tissue fluid in the face. J Physiol 1955, 130:72-78.
• [21]Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG: Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010, 56:1077-1082.
• [22]Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M: Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
• [23]Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A: Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58:559-565.
• [24]Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010, 24:532-537.
• [25]Officers A: Coordinators for the ACRGTA, lipid-lowering treatment to prevent heart attack T: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
• [26]Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
• [27]Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000, 35:1025-1030.
• [28]Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL: Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
• [29]Guerrero P, Fuchs FD, Moreira LM, Martins VM, Bertoluci C, Fuchs SC, Gus M: Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens 2008, 30:553-564.
• [30]Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, Value trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
• [31]Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, Investigators AT: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
• [32]Girvin BG, Johnston GD: Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents. J Hypertens 2004, 22:1409-1414.